Kenneth Truitt
Keine laufenden Positionen mehr
Profil
Kenneth Truitt served as Chief Medical Officer at Aquestive Therapeutics, Inc., ImmusanT, Inc., and Venthera, Inc.
Ehemalige bekannte Positionen von Kenneth Truitt
| Unternehmen | Position | Ende |
|---|---|---|
Venthera, Inc.
 Venthera, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Venthera, Inc. develops biopharmaceuticals. The company is based in Palo Alto, CA. The company was founded by José Baselga. | Technik-/Wissenschafts-/F&E-Leiter | - |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
| AQUESTIVE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AQUESTIVE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Venthera, Inc.
Venthera, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Venthera, Inc. develops biopharmaceuticals. The company is based in Palo Alto, CA. The company was founded by José Baselga. | Health Technology |
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |